Clinical trials of biosimilars should become more similar

Ann Rheum Dis. 2017 Jan;76(1):4-6. doi: 10.1136/annrheumdis-2015-208113. Epub 2016 Aug 25.

Authors

Jonathan Kay¹, John D Isaacs²

Affiliations

¹ Division of Rheumatology, Department of Medicine, UMass Memorial Medical Center and University of Massachusetts Medical School, Worcester, Massachusetts, USA.
² Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University and National Institute of Health Research Newcastle Biomedical Research Centre, Newcastle upon Tyne, UK.

PMID: 27566795
DOI: 10.1136/annrheumdis-2015-208113

No abstract available

Keywords: Anti-TNF; Disease Activity; Inflammation; Rheumatoid Arthritis; Treatment.

Publication types

Editorial
Comment

MeSH terms

Antirheumatic Agents*
Arthritis, Rheumatoid
Biosimilar Pharmaceuticals*
Infliximab
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Biosimilar Pharmaceuticals
Tumor Necrosis Factor-alpha
Infliximab

Grants and funding

G1001518/MRC_/Medical Research Council/United Kingdom